Evidence map›Paper›PMID 42742346›Full record

ArticleProtein science : a publication of the Protein Society2026

Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.

Hiroshi Itou, Kaori Sano, Akira Ainai, Kazushige Otsuki, Toshikazu Inoue, Takuya Hemmi, Hideki Hasegawa, Tadaki Suzuki

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.Protein science : a publication of the Protein Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroshi ItouChiome Bioscience Inc., Tokyo, Japan.ORCID 0009-0005-9898-8954
Kaori SanoInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-4887-1302
Akira AinaiDepartment of Infections Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kazushige OtsukiChiome Bioscience Inc., Tokyo, Japan.ORCID 0009-0002-7506-1820
Toshikazu InoueChiome Bioscience Inc., Tokyo, Japan.ORCID 0009-0002-5992-3769
Takuya HemmiDepartment of Infections Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-9782-9696
Hideki HasegawaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Tadaki SuzukiDepartment of Infections Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-3820-9542

Funding

Japan Agency for Medical Research and Development JP223fa627003Japan Agency for Medical Research and Development JP26fk0108732Japan Science and Technology Agency JPMJMS2025Ministry of Health, Labour and Welfare 26HA2015
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) provide insights for developing universal influenza vaccines through their ability to neutralize diverse viral strains. However, designing antigens that reliably elicit bNAb responses remains challenging due to the difficulty in targeting conserved epitopes with a single antigen. We developed a method using anti-idiotypic antibodies (IDs) to generate antigens that induce cross-reactive antibodies against diverse influenza A and B hemagglutinins. Our approach leverages IDs that mimic the conformational epitopes targeted by bNAbs. Structural analysis reveals conformational similarity between bNAb-ID and bNAb-HA-binding interfaces, providing mechanistic insight into molecular mimicry. These epitope-mimicking IDs function as effective immunogens, inducing highly cross-reactive antibodies. This study demonstrates the feasibility and structural basis of molecular mimicry-based antigen design for targeting conserved conformational epitopes. Although these findings establish proof of concept, vaccine applicability requires further investigation.

Indexed as

Antibodies, Anti-IdiotypicAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza A virusMolecular MimicryAnimalsAntibodies, NeutralizingCross ReactionsHumansInfluenza VaccinesModels, MolecularAntibodies, Anti-IdiotypicAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesantigen designanti‐idiotypic antibodiesbroadly neutralizing antibodiescross‐reactive antibodieshemagglutinininfluenza virusmolecular mimicryuniversal vaccine

Identifiers

PMID42742346
PMCPMC13576629

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.